Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9389844 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL1994288 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3BTRPV1 | |
| SCHEMBL1244094 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL3841301 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3B | |
| SCHEMBL3760858 | 0.77 | TPMT (0.65) | TPMTCA1CA2GSK3BPHGDH | |
| SCHEMBL4083603 | 0.76 | TPMT (0.55) | TPMTCA1CA2GSK3BTRPV1 | |
| SCHEMBL1498129 | 0.74 | TSHR (0.71) | TPMTCA1CA2TP53TSHR | |
| SCHEMBL213538 | 0.74 | LMNA (0.60) | CA1CA2PTPN1 | |
| SCHEMBL79334 | 0.74 | TPMT (1.00) | TPMTCA1CA2GSK3BRXRA | |
| SCHEMBL2163424 | 0.74 | TPMT (0.62) | TPMTCA1CA2GSK3BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-8524765-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130123265-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8389567-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120289587-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8263641-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5739287-A | BOUND ALSO TO A RECEPTOR MODULATING AGENT TO IMPEDE CELL SURFACE RECEPTOR TRAFFICKING PATHWAYS BY INHIBITING THE RECYCLING OF RECEPTORS TO THE CELL SURFACE; ANTITUMOR AND -CARCINOGENIC AGENTS; LEUKEMIA | UNIVERSITY OF WASHINGTON (US) | 1998-04-14 | — | — | US | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-5026705-A | Benzimidazolylpyridazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4923869-A | INOTROPIC, VASODILATING, AND ANTITHROMBOTIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289587-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TPMT 1869/4885CA1 1250/4885CA2 86/4885 |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TPMT 1869/4885CA1 1250/4885CA2 86/4885 |
| US-20130123265-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, ATP2A1 | TPMT 1737/4885CA1 1494/4885CA2 88/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TPMT 1869/4885CA1 1250/4885CA2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.